The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Subscribe To Our Newsletter & Stay Updated
